| Title |
HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration
|
|---|---|
| Published in |
Journal of Neuro-Oncology, November 2007
|
| DOI | 10.1007/s11060-007-9488-y |
| Pubmed ID | |
| Authors |
Rosaria Bassi, Paola Giussani, Viviana Anelli, Thomas Colleoni, Marco Pedrazzi, Mauro Patrone, Paola Viani, Bianca Sparatore, Edon Melloni, Laura Riboni |
| Abstract |
HMGB1 (high mobility group box 1 protein) is a nuclear protein that can also act as an extracellular trigger of inflammation, proliferation and migration, mainly through RAGE (the receptor for advanced glycation end products); HMGB1-RAGE interactions have been found to be important in a number of cancers. We investigated whether HMGB1 is an autocrine factor in human glioma cells. Western blots showed HMGB1 and RAGE expression in human malignant glioma cell lines. HMGB1 induced a dose-dependent increase in cell proliferation, which was found to be RAGE-mediated and involved the MAPK/ERK pathway. Moreover, in a wounding model, it induced a significant increase in cell migration, and RAGE-dependent activation of Rac1 was crucial in giving the tumour cells a motile phenotype. The fact that blocking DNA replication with anti-mitotic agents did not reduce the distance migrated suggests the independence of the proliferative and migratory effects. We also found that glioma cells contain HMGB1 predominantly in the nucleus, and cannot secrete it constitutively or upon stimulation; however, necrotic glioma cells can release HMGB1 after it has translocated from the nucleus to cytosol. These findings provide the first evidence supporting the existence of HMGB1/RAGE signalling pathways in human glioblastoma cells, and suggest that HMGB1 may play an important role in the relationship between necrosis and malignancy in glioma tumours by acting as an autocrine factor that is capable of promoting the growth and migration of tumour cells. |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Norway | 1 | 3% |
| Brazil | 1 | 3% |
| Unknown | 36 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 26% |
| Professor > Associate Professor | 6 | 16% |
| Researcher | 6 | 16% |
| Student > Master | 5 | 13% |
| Student > Bachelor | 3 | 8% |
| Other | 4 | 11% |
| Unknown | 4 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 14 | 37% |
| Medicine and Dentistry | 8 | 21% |
| Biochemistry, Genetics and Molecular Biology | 6 | 16% |
| Immunology and Microbiology | 2 | 5% |
| Chemistry | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 7 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 May 2023.
All research outputs
#7,536,586
of 22,994,508 outputs
Outputs from Journal of Neuro-Oncology
#1,064
of 2,987 outputs
Outputs of similar age
#25,980
of 77,137 outputs
Outputs of similar age from Journal of Neuro-Oncology
#3
of 7 outputs
Altmetric has tracked 22,994,508 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,987 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 77,137 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.